Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily,
orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and
tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium
(Spiriva Handihaler®) monotherapy on lung function in patients with COPD.